Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 10/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | SIK1 | P57059 | 1/20 | 0.53 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.53 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 5/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13878730 | 0.91 | LCK (0.55) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL13878728 | 0.87 | CSF1R (0.55) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL13878751 | 0.85 | CSF1R (0.57) | LCKCSF1RBRAFSRCLYN | |
| SCHEMBL30197903 | 0.84 | ABL1 (0.65) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL29381575 | 0.84 | ABL1 (0.65) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL1704785 | 0.84 | ABL1 (0.65) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL1704685 | 0.84 | RAF1 (0.54) | LCKCSF1RBRAFSRCINSR | |
| SCHEMBL13878724 | 0.83 | BRAF (0.64) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL1704263 | 0.83 | SIK1 (0.56) | LCKCSF1RKITBRAFSRC | |
| SCHEMBL1704880 | 0.83 | ABL1 (0.64) | LCKCSF1RKITBRAFSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960341-B1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3263717-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| US-20170315128-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| EP-2435581-B1 | METHODS OF USE OF A NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) | MOLECULAR HEALTH GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| EP-2960341-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Molecular Health GmbH (DE) | 2015-12-30 | — | — | EP | disclosed |
| EP-2492355-B1 | Tissue protective erythropoietin receptor (nepor) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2015-04-08 | — | — | EP | disclosed |
| US-20140296318-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| US-8357501-B2 | Tissue protective erythropoietin receptor (NEPOR) and methods of use | MOLECULAR HEALTH GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-2109690-B9 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245087-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2012-09-27 | — | — | US | disclosed |
| EP-2492355-A1 | Tissue protective erythropoietin receptor (nepor) and methods of use | Life Biosystems GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2109690-B1 | EPH-B4 SPECIFIC SIRNA FOR REDUCING EPO-INDUCED TUMOR CELL GROWTH DURING ANEMIA TREATMENT IN CANCER PATIENTS, TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE. | MOLECULAR HEALTH GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20090306186-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG | 2009-12-10 | — | — | US | disclosed |
| EP-2109690-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | Alepor GMBH & CO. KG (DE) | 2009-10-21 | — | — | EP | disclosed |
| WO-2009068677-A1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | ALEPOR GMBH & CO. KG (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | LCK 56/4885CSF1R 891/4885KIT 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.